Home
Royalty Pharma

Royalty Pharma Market Share Analysis for July 2026

We are the leading provider of funding solutions for life sciences innovation.

Health > Biotechnology and Pharmaceuticals

Domainroyaltypharma.com

Year Founded1996

Employees51 - 200

Annual Revenue> $1B

Royalty Pharma

Royalty Pharma (including company regionals)

royaltypharma.com

See more website traffic and engagement information

Royalty Pharma Revenue up to July 2026 is > 1B

revenue generated by Royalty Pharma top domains

Royalty Pharma top domains revenue over 3 years

Revenue for Royalty Pharma top domains

royaltypharma.com> 1B

See more with Sales Intelligence

Total visits to Royalty Pharma's top domains

Understand Royalty Pharma market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

royaltypharma.com9.6K

See more with Sales Intelligence

Avg. visit duration in Royalty Pharma's top domains

Analyze Royalty Pharma engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

royaltypharma.com00:01:19

See more with Sales Intelligence

Avg. pageviews on Royalty Pharma's top domains

See how Royalty Pharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

royaltypharma.com1.81

See more with Sales Intelligence

Royalty Pharma top competitors by domain

Top similar sites in July 2026, ranked by their affinity

sofinnovapartners.comCompany NameSofinnova PartnersEmployees51 - 200HQFrance, ParisAnnual revenue$2M - $5MTotal visits13.9KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Royalty Pharma

These are the website technologies, by industry, used by Royalty Pharma top domains

Conversion & Analytics (7)

Google Analytics

Advertising (3)

DoubleClick

Content Management System (3)

WordPress

Marketing (3)

Google Marketing Platform

More Technologies

11

See all

News & Signals from Royalty Pharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsRoyalty Pharma plc invested into assets: royalty interest in the amount of $425M in New York, New York, United States, Northern America, Americas on Jul 22nd '26.Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune.

NewsRoyalty Pharma was planning to invest into assets: royalty interest in the amount of $425M in New York, United States, Northern America, Americas on Jul 22nd '26.Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune.

NewsNeurimmune AG sold assets to Royalty Pharma in the amount of $425M on Jul 22nd '26.Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125 million upfront.